GLP-1 Gallbladder Attacks: What the Labels Say About Gallstones in Men
It might be. Gallstones and gallbladder inflammation are listed warnings on every major GLP-1 label, and the extra risk shows up most clearly in weight-loss trials. Steady pain in the upper right belly after a meal that lasts for hours is not typical GLP-1 nausea, and with fever, yellowing skin or eyes, or pain into the back, it needs same-day care.
Key takeaways
- In the Wegovy injection trials, gallstones were reported in 1.6% of patients vs. 0.7% on placebo; cholecystitis in 0.6% vs. 0.2%.
- Zepbound's label reports cholecystitis in 0.7% vs. 0.2% on placebo and says gallbladder events "were associated with weight reduction."
- Men start with lower gallstone risk than women, but fast weight loss raises risk regardless of sex.
- Pain lasting several hours, fever or chills, or jaundice during or after an attack means see a doctor right away, according to NIDDK.
- Ask your prescriber about the pace of weight loss and whether anything should change with your dose if you've had gallstones before.
What the labels actually say
Every semaglutide and tirzepatide label carries a warning titled "Acute Gallbladder Disease." The wording differs a bit by product, but the message is the same: gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis) happened more often on the drug than on placebo, and if gallstones are suspected, "gallbladder studies and appropriate clinical follow-up are indicated."
Here are the numbers from the current US prescribing information on DailyMed as of October 2026.
| Drug | Event | Drug | Placebo |
|---|---|---|---|
| Wegovy injection, 2.4 mg | Gallstones | 1.6% | 0.7% |
| Wegovy injection, 2.4 mg | Cholecystitis | 0.6% | 0.2% |
| Wegovy tablet | Gallstones | 2.5% | 1% |
| Zepbound, weight trials | Gallstones | 1.1% | 1% |
| Zepbound, weight trials | Cholecystitis | 0.7% | 0.2% |
| Zepbound, weight trials | Gallbladder removal | 0.2% | 0% |
| Ozempic 0.5 mg / 1 mg | Gallstones | 1.5% / 0.4% | 0% |
| Mounjaro | Acute gallbladder disease (combined) | 0.6% | 0% |
Source: US prescribing information on DailyMed for Wegovy (revised 6/2026), Zepbound (revised 8/2026), Ozempic (revised 5/2026) and Mounjaro (revised 8/2026). Trials differ in length and population, so don't compare drugs row by row.
A few details matter for reading this table. The Wegovy label says plainly that treatment "is associated with an increased occurrence of cholelithiasis and cholecystitis." The Zepbound label adds that "acute gallbladder events were associated with weight reduction," and that its sleep apnea trials showed similar gallstone rates to its weight-loss trials. The Ozempic label lists cholecystitis and gallbladder removal among reports received after approval, too.
The raw percentages look small. They are. But millions of men are on these drugs, and a 1-in-100 event at that scale means a lot of emergency room visits.
Why weight loss causes gallstones
The mechanism is not unique to GLP-1s. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), when you lose weight quickly, "your liver releases extra cholesterol into the bile," and fast loss can also keep the gallbladder from emptying properly. Concentrated, cholesterol-heavy bile sitting in a sluggish gallbladder is how stones form.
That's why NIDDK lists rapid weight loss, including the fast loss after weight-loss surgery, as a gallstone risk factor, and why it says losing weight at a slower pace may make gallstones less likely.
A 2022 meta-analysis in JAMA Internal Medicine pooled 76 randomized trials with 103,371 participants and found GLP-1 drugs raised the risk of gallbladder or biliary disease overall (relative risk 1.37), (He et al., JAMA Intern Med 2022). The signal was stronger in trials where the drugs were used for weight loss (relative risk 2.29), at higher doses, and with longer use. In other words, the risk tracks the same things that drive weight loss.
Men vs. women: lower baseline, same mechanism
NIDDK's gallstone fact page says gallstones affect 10 to 15 percent of the US population and that women are more likely to develop them than men. Older age, obesity, American Indian or Mexican American heritage, and fast weight loss also raise risk.
| Factor | Men | General population |
|---|---|---|
| Baseline gallstone risk | Lower than women | 10 to 15% of US adults have gallstones |
| Effect of rapid weight loss | Raises risk | Raises risk |
| Age | Risk rises with age | Risk rises with age |
| Sex-specific GLP-1 data on labels | Not reported | Not reported |
Source: NIDDK, Definition and Facts for Gallstones; GLP-1 labels on DailyMed.
The practical point: being male does not cancel out the risk from losing 15 or 20 percent of your body weight in a year. The labels do not break gallbladder rates out by sex, so there is no published basis for telling a man his risk on the drug is lower than a woman's. Men over 50 and men losing weight fast should treat the warning as fully applying to them.
Compare available care options
Look for a provider who checks in during titration and has a plan for side effects; a consult is not a prescription guarantee.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Gallbladder pain vs. ordinary GLP-1 stomach trouble
GI side effects are very common on these drugs. The Wegovy label reports nausea in 44% of adults on the 2.4 mg injection vs. 16% on placebo, and vomiting in 24% vs. 6%. So the challenge is spotting the gallbladder attack hidden among the expected queasiness.
NIDDK's symptom page describes a classic gallbladder attack this way:
- Pain in the upper right part of the belly.
- Often after heavy meals, and usually in the evening or during the night.
- Pain that can last several hours.
GLP-1 nausea usually feels like general queasiness or fullness rather than a pain you can point to. If your discomfort is a steady, localized pain under the right ribs rather than general queasiness, mention that difference specifically when you call.
The pancreatitis overlap
Gallstones and pancreatitis are linked: a stone that slips out of the gallbladder can block the duct the pancreas drains through. GLP-1 labels carry a separate pancreatitis warning. The Zepbound label describes the warning signs as "persistent or severe abdominal pain (sometimes radiating to the back)."
You don't need to sort out which organ is the problem at home. Severe belly pain that won't let up is an emergency either way, and the workup (blood tests, imaging) will tell the doctors which one it is.
What doctors typically check
The labels tell prescribers to order "gallbladder studies and appropriate clinical follow-up" when gallstones are suspected. That commonly means blood work and imaging of the upper abdomen, such as an ultrasound. Make sure the ER or urgent care team knows you're on a GLP-1, the dose, and when you last increased it. That history helps them interpret what they find.
Whether you stay on the drug, pause it, or change the dose after a gallbladder event is a decision for your prescriber and, if surgery is involved, your surgeon. The labels don't set a single rule for that.
Questions to ask about pacing your dose
NIDDK's position that slower weight loss may lower gallstone risk gives you a reasonable conversation to have with your prescriber, especially if you have had gallstones before or a family history of them. Questions worth bringing:
- Given how fast I'm losing, is my pace something we should slow down?
- Is it reasonable to stay longer at my current dose before the next increase?
- I've had gallstones before (or I still have my gallbladder with known stones). Does that change your plan?
- NIDDK says ursodiol can help prevent gallstones in people losing weight rapidly on very low-calorie diets or after surgery. Is that relevant to me?
- Which symptoms should send me to the ER instead of waiting to message you?
Very aggressive calorie restriction on top of a GLP-1 can speed loss further. If your intake has dropped very low, tell your prescriber.
If you've already had your gallbladder removed
Men who have had a cholecystectomy can't form new gallbladder stones, since the organ is gone. The other GI side effects and the pancreatitis warning still apply. Tell your prescriber about the surgery anyway, because it's part of the history they need.
Where this guide stops
This article summarizes US label language and NIDDK patient information as of October 2026. It can't tell you whether your pain is your gallbladder; only an exam and testing can. It doesn't cover compounded semaglutide or tirzepatide, which are not FDA-approved and don't carry their own trial-based label data. If you're in pain right now and it's severe, stop reading and get seen.
Find a prescriber who monitors titration
Compare telehealth options for FDA-approved GLP-1s and read each provider's follow-up and side-effect policies directly.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
Do GLP-1 drugs cause gallstones?
They raise the risk. The Wegovy injection label reports gallstones in 1.6% of patients vs. 0.7% on placebo, and the Zepbound label says gallbladder events were associated with weight reduction.
Are men at lower risk of gallstones on a GLP-1?
Men have lower baseline gallstone risk than women, according to NIDDK, but rapid weight loss raises risk regardless of sex, and the labels don't report gallbladder rates by sex.
How do I tell gallbladder pain from GLP-1 nausea?
A gallbladder attack typically causes pain in the upper right belly, often after heavy meals and in the evening or night, that can last several hours. General queasiness or fullness is more typical of GLP-1 nausea.
When is gallbladder pain an emergency?
NIDDK says to see a doctor right away for belly pain lasting several hours, fever or chills, or yellowing of the skin or eyes. Severe, persistent pain that spreads to the back can also signal pancreatitis.
Can slowing weight loss lower gallstone risk?
NIDDK says losing weight at a slower pace may make gallstones less likely. Whether to slow your dose increases is a question for your prescriber.
Sources
- DailyMed: Wegovy (semaglutide) prescribing information
- DailyMed: Zepbound (tirzepatide) prescribing information
- DailyMed: Ozempic (semaglutide) injection prescribing information
- DailyMed: Mounjaro (tirzepatide) prescribing information
- NIDDK: Dieting and Gallstones
- NIDDK: Definition and Facts for Gallstones
- NIDDK: Symptoms and Causes of Gallstones
- He L et al. Association of GLP-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med 2022;182(5):513-519
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.